Trials / Recruiting
RecruitingNCT06227377
QTX3034 in Patients With KRAS G12D Mutation
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- Quanta Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QTX3034 | QTX3034 will be administered at protocol defined dose |
| COMBINATION_PRODUCT | Cetuximab | Cetuximab will be administered at protocol defined dose. |
Timeline
- Start date
- 2024-02-05
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2024-01-26
- Last updated
- 2025-12-24
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06227377. Inclusion in this directory is not an endorsement.